HCP
66
8
MLM
57
6
CINF
53
2
KHC
24
13
CAH
48
-5
MSFT
50
3
VZ
50
3
TJX
64
2
NWL
53
3
GPC
40
3
NKE
36
6
DNB
82
4
HRB
57
5
HPQ
63
6
SE
61
-4
ILMN
42
5
VTR
47
-7
LRCX
43
-2
UNP
52
7
PYPL
54
2
HCP
66
8
MLM
57
6
CINF
53
2
KHC
24
13
CAH
48
-5
MSFT
50
3
VZ
50
3
TJX
64
2
NWL
53
3
GPC
40
3
NKE
36
6
DNB
82
4
HRB
57
5
HPQ
63
6
SE
61
-4
ILMN
42
5
VTR
47
-7
LRCX
43
-2
UNP
52
7
PYPL
54
2
Financhill
Back

Stoke Therapeutics 10K Form

Sell
35

STOK
Stoke Therapeutics

Last Price:
11.43
Seasonality Move:
14.28%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive STOK News And Ratings

See the #1 stock for the next 7 days that we like better than STOK

STOK Financial Statistics

Sales & Book Value

Annual Sales: $8.78M
Cash Flow: $-21.72M
Price / Cash Flow: 0
Annual Sales: $4.38
Price / Book: 2.61

Profitability

EPS (TTM): -2.10000
Net Income (TTM): $-105.46M
Gross Margin: --
Return on Equity: -55.64%
Return on Assets: -41.37%

Stoke Therapeutics Earnings Forecast

Key Stoke Therapeutics Financial Ratios

  • The Research & Development expenses have been 936.57% of Revenue.
  • The Net Earning history of STOK is -1,192.47% of Total Revenues.
  • Per Share Earnings over the last 7 years have been positive in 2 years.

Stoke Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: STOK
CUSIP: 86150R
Website: stoketherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.09
Quick Ratio: 4.81

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

STOK Technical Analysis vs Fundamental Analysis

Sell
35
Stoke Therapeutics (STOK) is a Sell

Is Stoke Therapeutics a Buy or a Sell?